Search results
Showing 16 to 28 of 28 results for irinotecan
Evidence-based recommendations on ramucirumab (Cyramza) for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy.
Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma in adults after 2 or more treatments.
Evidence-based recommendations on paclitaxel as albumin-bound nanoparticles (nab-paclitaxel; Abraxane) for untreated metastatic pancreatic cancer in adults.
In development [GID-TAG380] Expected publication date: TBC
Evidence-based recommendations on pembrolizumab (Keytruda) for treating metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency in adults.
Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer [ID1357]
Discontinued [GID-TA10322]
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]
In development [GID-TA11228] Expected publication date: TBC
Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (DG16)
Evidence-based recommendations on the My5-FU assay for measuring levels of 5-flurouracil (5-FU) in patients having chemotherapy, to help guide changes to the
Immunoscore for predicting risk of colon cancer relapse (MIB269)
NICE has developed a medtech innovation briefing on Immunoscore for predicting risk of colon cancer relapse .
Colorectal cancer (advanced) - irinotecan, oxaliplatin and raltitrexed (TA93)
This guidance has been updated and replaced by NICE guideline NG151. The recommendations on raltitrexed have been withdrawn because its use is established clinical practice.
Evidence-based recommendations on nivolumab (Opdivo) plus ipilimumab (Yervoy) for untreated unresectable or metastatic colorectal cancer with high microsatellite instability in adults.
Caris Molecular Intelligence for guiding cancer treatment (MIB120)
NICE has developed a medtech innovation briefing (MIB) on Caris Molecular Intelligence for guiding cancer treatment .
This guidance has been replaced by NICE technology appraisal guidance 93 [Replaced by NICE guideline CG131].